The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s research includes a study on a targeted therapy combination for treating low-grade childhood glioma with a BRAF V600 mutation.
2022 ASCO Annual Meeting: Advances in Treating Breast Cancer, Colorectal Cancer, Ewing Sarcoma, and Multiple Myeloma
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include advances in treating HER2-low metastatic breast cancer, RAS wild-type metastatic colorectal cancer, recurrent and refractory Ewing sarcoma, and newly diagnosed multiple myeloma.
2022 ASCO Annual Meeting: Targeted Therapy for Advanced HR-Positive, HER2-Negative Breast Cancer and Using Liquid Biopsy to Guide Treatment for Stage II Colon Cancer
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include targeted therapy for advanced hormone receptor-positive, HER2-negative breast cancer and using liquid biopsy to guide post-surgery treatment decisions for stage II colon cancer.
2022 ASCO Annual Meeting: Improving Standard Care for Advanced Pancreatic Cancer and Older Adults with Mantle Cell Lymphoma
The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s studies explore adding nimotuzumab to chemotherapy to treat KRAS wild-type pancreatic cancer and adding ibrutinib to standard care for older adults with mantle cell lymphoma.
New Research in Treating Lymphoma and Improving Equity in Cancer Clinical Trials: ASH Annual Meeting 2021
In this podcast, Dr. Christopher Flowers discusses research from the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, including studies evaluating new treatments for diffuse large B-cell lymphoma and an overview of a session on improving equity in cancer clinical trials.
Targeted Therapy for Treating Advanced Gastrointestinal Stromal Tumors (GISTs): The ASCO Plenary Series
Read research from the January 2022 session of the ASCO Plenary Series, which highlights a study comparing 2 targeted therapies in treating advanced gastrointestinal stromal tumors (GISTs).
Stage IV lung cancer survivor Frank Sierawski shares what it was like being diagnosed with cancer at age 35 and how he learned to cope with the diagnosis by living in the moment.
In this podcast, 4 experts discuss the first-ever targeted therapies approved for people with non-small cell lung cancer with an epidermal growth factor receptor (EGFR) exon 20 insertion mutation, including how they work and what they mean for people with this type of cancer.
Immunotherapy Combinations for Treating Metastatic Melanoma and Using Technology to Find and Treat Symptoms Early: The ASCO Plenary Series
Research from the first ASCO Plenary Series presentation has arrived. Read more about studies on using immunotherapy to treat metastatic melanoma and how technology can be used to find and manage symptoms during cancer treatment.
2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain Tumors, Esophageal Cancer, and Colorectal Cancer
In this podcast, Cancer.Net Associate Editors discuss new research presented at the 2021 ASCO Annual Meeting on brain tumors, esophageal cancer, and colorectal cancer.